Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 9, 2014, Pages 1326-1338

  Daly, Mary B ^a   Pilarski, Robert ^b   Axilbund, Jennifer E ^c   Buys, Saundra S ^d   Crawford, Beth ^e   Friedman, Susan ^f   Garber, Judy E ^g   Horton, Carolyn ^h   Kaklamani, Virginia ⁱ   Klein, Catherine ^j   Kohlmann, Wendy ^d   Kurian, Allison ^k   Litton, Jennifer ^l   Madlensky, Lisa ^m   Marcom, P Kelly ⁿ   Merajver, Sofia D ^o   Offit, Kenneth ^p   Pal, Tuya ^q   Pasche, Boris ^r   Reiser, Gwen ^s   Shannon, Kristen Mahoney ^t   Swisher, Elizabeth ^u   Voian, Nicoleta C ^v   Weitzel, Jeffrey N ^w   Whelan, Alison ^x   Wiesner, Georgia L ^y   Dwyer, Mary A ^z   Kumar, Rashmi ^z   more..

^a FOX CHASE CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f FORCE Facing Our Risk of Cancer Empowered   (United States)

^g Dana Farber Brigham and Women's Cancer Center   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j University of Colorado Cancer Center   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁿ DUKE CANCER INSTITUTE   (United States)

^o UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^r UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^s NEBRASKA MEDICAL CENTER   (United States)

^t MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^u SEATTLE CANCER CARE ALLIANCE   (United States)

^v ROSWELL PARK CANCER INSTITUTE   (United States)

^w CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^x BARNES JEWISH HOSPITAL   (United States)

^y VANDERBILT INGRAM CANCER CENTER   (United States)

^z NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT DISEASE; ARTICLE; BANNAYAN RILEY RUVALCABA SYNDROME; BREAST CANCER; CONSENSUS DEVELOPMENT; COWDEN SYNDROME; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HAMARTOMA; HUMAN; LHERMITTE DUCLOS DISEASE; ONCOLOGY; OVARY CANCER; PRACTICE GUIDELINE; PTEN HAMARTOMA TUMOR SYNDROME; RISK ASSESSMENT; DISEASE MANAGEMENT; FEMALE; GENETICS; GERMLINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; MALE;

DISEASE MANAGEMENT; FEMALE; GENETIC COUNSELING; GENETIC TESTING; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE;

EID: 84907298200     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0127     Document Type: Article

References (46)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
2. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-141.
3. Lynch HT, Watson P, Conway TA, Lynch JF. Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat 1990;15:63-71.
4. Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800-809.
5. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 2007;16:241-260.
6. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008;359:2143-2153.
7. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 2004;13:83-114.
8. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-36.
9. Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008;27:5387-5397.
10. Eng C. PTEN hamartoma tumor syndrome (PTHS). In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2014. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1488/. Accessed August 5, 2014.
11. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009;18:13-27.
12. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011;48:505-512.
13. Varga EA, Pastore M, Prior T, et al. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med 2009;11:111-117.
14. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009;11:687-694.
15. Lloyd KM 2nd, Dennis M. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963;58:136-142.
16. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999;7:267-273.
17. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004;41:323-326.
18. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986;29:222-233.
19. Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010;8:6.
20. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400-407.
21. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50:255-263.
22. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer 1978;41:2393-2398.
23. Harach HR, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999;3:331-340.
24. Zbuk KM, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol 2007;4:492-502.
25. Black D, Bogomolniy F, Robson ME, et al. Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol 2005;96:21-24.
26. Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114-116.
27. Schaffer JV, Kamino H, Witkiewicz A, et al. Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol 2006;142:625-632.
28. Jazaeri AA, Lu K, Schmandt R, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53-59.
29. Brownstein MH, Mehregan AH, Bikowski JB, et al. The dermatopathology of Cowden's syndrome. Br J Dermatol 1979;100:667-673.
30. Brownstein MH, Mehregan AH, Bilowski JB. Trichilemmomas in Cowden's disease. JAMA 1977;238:26.
31. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010;139:1927-1933.
32. Al-Thihli K, Palma L, Marcus V, et al. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol 2009;6:184-189.
33. Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/ Akt pathway. Am J Hum Genet 2003;73:404-411.
34. Andres RH, Guzman R, Weis J, et al. Lhermitte-Duclos disease with atypical vascularization-case report and review of the literature. Clin Neuropathol 2009;28:83-90.
35. Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005;42:318-321.
36. Herman GE, Butter E, Enrile B, et al. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am J Med Genet A 2007;143:589-593.
37. Herman GE, Henninger N, Ratliff-Schaub K, et al. Genetic testing in autism: how much is enough? Genet Med 2007;9:268-274.
38. Orrico A, Galli L, Buoni S, et al. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. Clin Genet 2009;75:195-198.
39. Roche AF, Mukherjee D, Guo SM, Moore WM. Head circumference reference data: birth to 18 years. Pediatrics 1987;79:706-712.
40. Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992;44:307-314.
41. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507-515.
42. Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011;88:42-56.
43. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000;37:828-830.
44. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003;22:183-198.
45. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013;105:1607-1616.
46. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Thyroid Cancer. Available at: http://seer.cancer.gov/statfacts/html/thyro.html. Accessed August 5, 2014.